Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Annals of Oncology

Volumn 18, Issue 1, 2007, Pages 45-51

  Kennecke, H F ^a,b   Olivotto, I A ^a,b   Speers, C ^a   Norris, B ^a,b   Chia, S K ^a,b   Bryce, C ^a,b   Gelmon, K A ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast cancer; Estrogen receptor; Mortality; Relapse; Risk; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANADA; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MONOTHERAPY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL TIME; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; BRITISH COLUMBIA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TAMOXIFEN; TRIAZOLES;

EID: 33846550085     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl334     Document Type: Article

References (26)

1. Saphner T, Tormey DC, Gray R et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 114: 2738-2746.
2. Rosen PP, Groshen S, Kinne DW et al. Prognosis in T2N0M0 stage I breast carcinoma: A 20-year follow-up study. J Clin Oncol 1991; 9: 1650-1661.
3. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-90.
4. Stewart HJ, Forrest AP, Everington D et al. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-299.
5. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996; 88: 1828-1833.
6. Rowan TC, Collyar CE, Somerfield MR et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 1999; 17: 1939-1955.
7. Lippman ME, Krueger KA, Eckert S et al. Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001; 19: 3111-3116.
8. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
9. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: Updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005; 97: 1262-1271.
10. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausl women with early stage breast cancer: Results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety analyses. Cancer 2003; 98: 1802-1810.
11. Howell A, Cuzick J, Baum M et al. Results of the ATAC (arimidex, tamoxifen alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
12. The Breast International (BIG) 1-98 Collaborative Group. A comparison of letrozole with tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2457.
13. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
14. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
15. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancers: Status report 2004. J Clin Oncol 2005; 23: 619-629.
16. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual, 9th edition. Volume XIV. New York: Springer 2002
17. Olivotto IA, Coldman AJ, Hislop TG et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 1997; 15: 216-222.
18. Perou CM. Developmental and therapeutic implications of the molecular portraits of breast tumors. Mini-Symposium. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 8-11 December 2005
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687-1717.
20. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on primary early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
21. Cui X, Schiff R, Arpino G et al. The biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-7735.
22. Arpino G, Weiss H, Lee AV et al. Estrogen-positive, progesterone-negative breast cancer: Association with growth factor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-1261.
23. Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17: 818-826.
24. Chia SK, Speers CH, Bryce CJ et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004; 22: 1630-1637.
25. Sawka C, Olivotto I, Coldman A et al. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. Br J Cancer 1997; 75: 1534-1542.
26. Cameron DA, Kerr G, Jack W et al. Does everyone need letrozole after 5 years' tamoxifen and breast conserving surgery? Breast Cancer Res Treat 2004; 88 (Suppl 1): S22.